The Metastatic Uveal Melanoma drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Uveal Melanoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued products.
GlobalData tracks 41 drugs in development for Metastatic Uveal Melanoma by 29 companies/universities/institutes. The top development phase for Metastatic Uveal Melanoma is phase ii with 25 drugs in that stage. The Metastatic Uveal Melanoma pipeline has 38 drugs in development by companies and three by universities/ institutes. Some of the companies in the Metastatic Uveal Melanoma pipeline products market are: Bristol-Myers Squibb, Pfizer and Lyvgen Biopharma.
The key targets in the Metastatic Uveal Melanoma pipeline products market include Programmed Cell Death Protein 1, Cytotoxic T Lymphocyte Protein 4, and Dual Specificity Mitogen Activated Protein Kinase Kinase 1.
The key mechanisms of action in the Metastatic Uveal Melanoma pipeline product include Programmed Cell Death Protein 1 Antagonist with five drugs in Phase II. The Metastatic Uveal Melanoma pipeline products include 13 routes of administration with the top ROA being Intravenous and six key molecule types in the Metastatic Uveal Melanoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Metastatic Uveal Melanoma overview
Metastatic uveal melanoma is a rare and aggressive form of cancer that originates in the pigmented cells of the eye, specifically in the uvea, which includes the iris, ciliary body, and choroid. While the primary tumor in the eye may be treatable, metastatic spread of uveal melanoma to other parts of the body, such as the liver, lungs, bones, or other organs, is associated with a poor prognosis. Uveal melanoma is the most common primary intraocular malignancy in adults. Initially, it may cause few symptoms or be asymptomatic. Common signs include changes in vision, such as blurred vision, visual disturbances, or seeing flashes of light. In some cases, a dark spot on the iris or sudden onset of floaters may be observed. Despite successful treatment of the primary tumor, up to 50% of patients with uveal melanoma will eventually develop metastatic disease, often involving the liver as the most common site of spread. Metastases to other organs, including the lungs, bones, and skin, can also occur. Risk factors for metastatic uveal melanoma include larger tumor size, older age, certain genetic mutations, and specific characteristics of the primary tumor, such as the presence of specific genetic abnormalities. Diagnosis involves a comprehensive eye examination by an ophthalmologist, which may include specialized tests such as ultrasound, fluorescein angiography, or optical coherence tomography. Confirmation of uveal melanoma may require a biopsy of the eye or fine-needle aspiration biopsy.
For a complete picture of Metastatic Uveal Melanoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
